A Multicentre Study on Features of the Gut Microbiota of Patients With Critical Chronic Diseases in China
Launched by ZHUJIANG HOSPITAL · Nov 25, 2022
Trial Information
Current as of February 05, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the gut microbiota, which is the community of bacteria and other microorganisms living in our intestines, in patients with serious chronic diseases like various types of cancer, heart issues, and kidney diseases. Researchers want to understand how the gut microbiota differs among patients with these conditions and how it might help in creating better diagnostic tools, which are tests that help doctors identify diseases.
To participate in this study, you need to be between 18 and 75 years old and have been diagnosed with one of the specific diseases being studied. You also need to have lived in the same province as the hospital for the last three years and be willing to sign a consent form agreeing to participate. If you join, you can expect to provide some samples and answer questions about your health. It's important to note that some people, such as those who are pregnant or have recently taken certain medications, won't be eligible. This study is currently recruiting participants, so if you or someone you know fits the criteria, it might be a good opportunity to contribute to important health research.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. aged 18-75 years;
- • 2. living in the province where the hospital is located in the last three years;
- • 3. with a medical diagnosis of one of the target diseases;
- • 4. willing to provide written informed consent.
- Exclusion Criteria:
- • 1. female in pregnancy or lactation(unless the subject is pregnant women);
- • 2. with medical diagnoses of other serious illnesses;
- • 3. with a history of bariatric surgery or intestinal resection, except for appendectomy;
- • 4. individual who was treated with drugs in the preceding 1 month, including antibiotics, metformin, statins, acid inhibitor, probiotics, and probiotics; individuals having consumed yogurt more than 3 times in the preceding 1 month; heavy drinkers who have consumed more than 4 taels of liquor or 1000ml of beer; frequent alcohol consumers who have drunk per week in the last month.
Trial Officials
Yan He
Study Chair
Zhujiang Hospital
About Zhujiang Hospital
Zhujiang Hospital, affiliated with the Southern Medical University in Guangzhou, China, is a leading clinical research institution dedicated to advancing medical science and improving patient care through rigorous clinical trials. With a strong commitment to ethical standards and patient safety, the hospital boasts a multidisciplinary team of experienced researchers and healthcare professionals. Its state-of-the-art facilities enable the execution of innovative studies across various therapeutic areas, contributing valuable insights to the global medical community. Zhujiang Hospital aims to foster collaboration with academic institutions, pharmaceutical companies, and regulatory bodies to ensure the successful development of new therapies and enhance treatment options for patients.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Nanning, Guangxi, China
Fuzhou, Fujian, China
Wuxi, Jiangsu, China
Fuzhou, Fujian, China
Lanzhou, Gansu, China
Lanzhou, Gansu, China
Taiyuan, Shanxi, China
Zhuzhou, Hunan, China
Kunming, Yunnan, China
Guiyang, Guizhou, China
Xiangyang, Hubei, China
Fuzhou, Fujian, China
Ningbo, Zhejiang, China
Nanning, Guangxi, China
Chaoyang, Beijing, China
Nanchuan, Chongqing, China
Yongchuan, Chongqing, China
Foshan, Guangdong, China
Guangzhou, Guangdong, China
Shenzhen, Guangdong, China
Zhongshan, Guangdong, China
Tongliao, Guangxi, China
Guiyang, Guizhou, China
Haikou, Hainan, China
Daqing, Heilongjiang, China
Harbin, Heilongjiang, China
Harbin, Heilongjiang, China
Jixi, Heilongjiang, China
Qiqihar, Heilongjiang, China
Luoyang, Henan, China
Luoyang, Henan, China
Shangqiu, Henan, China
Wuhan, Hubei, China
Xianyang, Hubei, China
Wuzhou, Inner Mongolia Autonomous Region, China
Ji'an, Jiangxi, China
Ganzhou, Jiangx, China
Nanchang, Jiangx, China
Changzhi, Shanxi, China
Taiyuan, Shanxi, China
Xi'an, Shanxi, China
Xi'an, Shanxi, China
Chengdu, Sichuan, China
Guang'an, Sichuan, China
Leshan, Sichuan, China
Beichen, Tianjin, China
Binhai, Tianjin, China
Hexi, Tianjin, China
Kashgar, Xinjiang Uygur Autonomous Region, China
Qujing, Yunnan, China
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0
Similar Trials